Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (1679)	7/1/2003 3:19:38 PM
From: Biomaven	Read Replies (1) \| Respond to of 3044

Ian, I'd guess that by "analogues" they mean tweaked versions of the Velcade molecule. "Derivatives" could be further removed from the original molecule - perhaps the same concept done with a totally new molecule. But Miljenko is better qualified to answer this than I am. Peter (Edit: Although now that I think of it some more, "analogues" (or more commonly in the US "analogs") can be quite different molecules that work in the same way as the original molecule. So maybe my answer isn't correct. When the elided agreement is filed you might well be able to figure out the actual distinction they had in mind).